Cardiovascular Risk in Calcium Pyrophosphate Deposition Disease Save

The cardiovascular (CV) risks of inflammation and gout are well known, but until recently hasn't been tied to calcium pyrophosphate deposition (CPPD) disease. A recent EHR study shows that acute CPPD crystal arthritis was significantly associated with elevated risks for non-fatal CV events.

Data was extracted from Mass General Brigham electronic health records (EHR), between 1991–2017 They identified and matched 1200 acute CPP crystal arthritis patients to 3810 comparators. CV outcomes included major adverse cardiovascular event (MACE) was a composite of non-fatal CV event (myocardial infarction, acute coronary syndrome, coronary revascularisation, stroke) and death.

When they compared patients with acute CPPD arthritis to controls:

• Higher MACE events in years 0–2 (91/1000 person-years (p-y) vs 59/1000 p-y in comparators. (Between years 2–10, risk of MACE events was the same: 58 vs 53 per 1000PY)
• Acute CPP crystal arthritis had a significantly higher risk of MACE in years 0–2 (HR 1.32, 95% CI 1.01 to 1.73) and non-fatal CV event in years 0–2 (HR 1.92, 95% CI 1.12 to 3.28) and years 2–10 (HR 2.18, 95% CI 1.27 to 3.75).
• CV death rates were not increased.

Those who experienced acute CPP crystal arthritis had a significantly increased short and long-term risk for non-fatal CV events.